Imvax is a biotechnology company that develops vaccines and immunotherapy strategies for the treatment of malignant gliomas and other cancers. It produces IGV-001, an autologous tumor cell vaccine that delivers a multi-pronged response against tumor cells by leveraging the patient’s immune system as a defense mechanism.